Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

1987 • 1,845 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

The Glucagon-Like Peptides

1999 • 1,018 citations

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

1997 • 799 citations

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

1993 • 661 citations

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

2000 • 644 citations

Glucagon-like peptide-1: a potent regulator of food intake in humans

1999 • 564 citations

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

1999 • 516 citations

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

2002 • 498 citations

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

1999 • 454 citations

Minireview: The Glucagon-Like Peptides

2001 • 393 citations

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1999 • 335 citations

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

1995 • 313 citations

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men

1998 • 298 citations

Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes?

2000 • 292 citations

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

1996 • 286 citations

Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects

1992 • 282 citations

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

2002 • 269 citations

Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

1996 • 225 citations

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

1995 • 199 citations

Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment

2001 • 172 citations

Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +/?)*

1999 • 153 citations

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1994 • 138 citations

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7?36 amide] in the fasting state in healthy subjects

1995 • 101 citations

A Radioimmunoassay for LY315902 an analog of Glucagon-like Insulinotropic Peptide, and Its Application in the Study of Canine Pharmacokinetics

1997 • 18 citations

Effect of the protracted GLP-1 derivative NN2211 in betacell reduced minipig

2000 • 1 citations